The Life Science Institute, Inc. (LSII) Group was established in 2014 to enhance and expand the healthcare business of the Mitsubishi Chemical Holdings Group. After subsequent reorganization, the API Corporation is now operating under LSII.
In Japan today, reducing medical costs has become a major social and political issue due to the declining birthrate and aging population. The realization of a society where everyone can live a healthy and peaceful life, called KAITEKI, is a fitting solution toward our common wish for a desirable society. To this end, the LSII Group acts as a partner that provides new value through comprehensive healthcare solutions, standing with patients suffering from rare and intractable diseases who wish to lead healthy lives. Specifically, this entails contributing to society through our Next-generation Healthcare segment by developing new possibilities through regenerative medicine, initiatives in Healthcare/Medical Information & Communication Technology to create new medical care innovations utilizing digital technologies, and Pharmaceutical Development Solutions that support a stable supply of active pharmaceutical ingredients and intermediates through Open Shared Business (OSB)*1 and innovation.
We believe that the following three criteria for healthcare solutions are intrinsic for creating new value and contributing to society. The first criterion is "Value." Is the solution truly valuable? Does the solution respond to unmet medical needs*2? Can the solution become an essential asset that surpasses existing treatment options? The second criterion is "Accessibility." Can the solution be used across a wide portion of society? Is the solution conveniently available at a reasonable price? The third criterion is "Sustainability." Can the solution continue to be provided in the future? Can a sound business and stable supply be maintained?
The LSII Group builds businesses that satisfy these three criteria via healthcare solutions, and maintains a strong competitive edge through synergy created by working closely with MCHC Group companies.
The LSII Group is committed to realizing KAITEKI by delivering hope to individuals suffering from illness and contributing to a society that maintains good physical and mental health.
*1 Open Shared Business (OSB): OSB is the original framework of the Mitsubishi Chemical Holdings Group (MCHC) for working with organizations outside MCHC. We promote collaboration in the R&D distinctive value chain using the OSB framework. OSB: MCHC registered trademark No. 5585432.
*2 Unmet medical needs: Conditions for which there are currently no satisfactory diagnosis, prevention, or treatment methods available